Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12

13 septembre 2018

08:00
Hoffmann-La Roche Limitée (Roche Canada) a annoncé aujourd'hui que Santé Canada a approuvé une préparation sous-cutanée de HERCEPTIN (HERCEPTIN SC) pour le traitement du cancer du sein métastatique au stade précoce surexprimant le récepteur 2 du...

07:00
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA® (aflibercept) Injection for the treatment of diabetic...

06:20
AbbVie , a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in adult patients with...

06:16
BioArctic AB (publ) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). BBS was founded by the internationally well-known researchers in the area of Alzheimer diagnostics, Professors Kaj Blennow and Henrik...


12 septembre 2018

19:00
Vanda Pharmaceuticals Inc. (Vanda) today announced the results of a HETLIOZ® (tasimelteon) driving study to measure next day performance.  Tasimelteon did not impair measures of driving performance, whereas the active control, zopiclone, showed...

17:02
Novartis today announced that The New England Journal of Medicine (NEJM) has published full results from the landmark Phase III Gilenya® (fingolimod) PARADIGMS study, the first-ever global, completed, controlled, randomized study specifically...

15:41
ExeGi Pharma is pleased to announce two new clinical partnerships with the College of Veterinary Medicine at the University of Georgia and the University of Tennessee to study the Visbiome Vet probiotic in domestic dogs. Both studies will evaluate...

14:06
The American Society of Hematology (ASH) is launching a sickle cell disease (SCD) clinical trials network in order to accelerate the development of new therapies for a patient community that has very few treatments and curative options....

14:00
Using new bioinformatics tools to analyze thousands of human tissue samples, researchers at Cincinnati Children's Hospital Medical Center created a new database of daily rhythms in human gene activity?including many genes that regulate how drugs...

11:00
Quantum Leap Healthcare Collaborativetm (QLHC), a non-profit organization and sponsor of the I-SPY 2 TRIALtm, today presented for the first time at the National Press Club, an overall view of the remarkable progress achieved by the I-SPY 2 clinical...

10:07
Mitra Biotech today announced a partnership with Glenmark Pharmaceuticals focused on advancing Glenmark's proprietary immuno-oncology drug pipeline utilizing Mitra's CANscriptTM platform. CANscript is a human,...

09:47
Amygdala Neurosciences (a private company) announced today that the National Institute on Alcohol Abuse and Alcoholism (NIAAA, a division of NIH) will fund and conduct a Phase 2, human laboratory study of ANS-6637 for the treatment of alcohol use...

09:00
La Société canadienne de la sclérose en plaques a annoncé aujourd'hui un investissement de cinq millions de dollars destiné à financer le premier essai clinique multicentrique international dont les auteurs auront pour objectif de...

09:00
The Multiple Sclerosis Society of Canada announced today a $5 million grant in support of the first, international, multicenter clinical trial to investigate cognitive rehabilitation and aerobic exercise in improving cognition in people with...

08:42
A subset of children with autism spectrum disorder (ASD), who have an immune abnormality, may benefit from intravenous immunoglobulin (IVIg) treatment, according to new research from Richard E. Frye, MD, PhD, Chief of Neurodevelopmental Disorders at...

08:30
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for rare and common malignancies, today announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal...

08:00
Boehringer Ingelheim today announced results from a phase III study, confirming that Cyltezo® is equivalent to Humira®*, with no clinically meaningful differences in efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque...

08:00
According to a new market research report "Rapid Microbiology Testing Market by Method (Growth, Viability), Product (Automated Microbial Identification & AST System, PCR, Reagent), Application (Clinical Diagnosis, Environmental), End User (Labs,...

06:19
Biohaven Pharmaceutical Holding Company Ltd. , a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug...

06:00
ApoCell, Inc., a pioneer in customized biomarker solutions, today announced the offer of services using the PerkinElmer Vectra® Polaristm System Automated Quantitative Pathology Imaging System in combination with the company's platform technology to...

05:37
Illustrating the challenges of developing medicines to fight Alzheimer's disease, a new analysis from the Pharmaceutical Research and Manufacturers of America (PhRMA) found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical...

01:12
Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, is pleased to note that pre-clinical data from its ONCOS oncolytic virus program has been published in two leading,...


11 septembre 2018

23:30
A recent circular issued by the Chinese State Drug Administration (SDA), has opened up a large market for Contract Research Organizations (CROs) across the world. The circular (referred to as No. 52 of 2018) allows Chinese pharmaceutical companies to...

16:22
Theravance Biopharma, Inc. ("Theravance Biopharma") and Mylan N.V. ("Mylan") today announced that new data from the Phase 3 YUPELRItm (revefenacin) inhalation solution clinical program will be featured in an oral presentation at the European...

16:00
Regen BioPharma Inc. and has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently-identified, novel chemical compounds appear to inhibit NR2F6 and thus can potentially be developed...

10:00
Provista Diagnostics today announced the results of its latest clinical study of its simple blood test to further validate its proteomic biomarker assay, Videssa®. The article titled "A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay...

08:30
TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that two papers have been published reporting on recent clinical...

08:28
Not intended for UK-based media First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type Results significant in PDL1+ and all-comer populations Alliance plans to pursue a regulatory...

08:17
AbbVie , a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA® (venetoclax tablets) in combination with rituximab to include information about patients...

08:00
PolarityTE, Inc. , a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine,...

08:00
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the publication of new patient-reported outcomes (PRO) data demonstrating that adding ERLEADA® (apalutamide) to androgen-deprivation therapy (ADT) in patients with...

07:05
Twenty-seven percent of people living with depression or bipolar report that their symptoms began before age 12 and two-thirds reported that symptoms began prior to age 18. These preliminary findings are the result of a survey fielded by the Milken...

07:00
AcelRx Pharmaceuticals, Inc. , (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the Anesthetic and Analgesic Drug Products Advisory Committee of the...

05:45
Global E-clinical Trials Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are rising enormously across the globe. E-clinical Trials is termed as a trial automation technology used to derive the...

05:00
Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the publication of two-year data from a Centers for Medicare & Medicaid Services (CMS)-approved study,...

01:00
The Albert and Mary Lasker Foundation today announced the winners of its 2018 Lasker Awards: C. David Allis from Rockefeller University and Michael Grunstein from the University of California, Los Angeles will receive the Albert Lasker Basic Medical...


10 septembre 2018

20:28
ATP Science Pty Ltd and Research Fellow Dr Miaomiao Liu from the Griffith Institute for Drug Discovery have been awarded the Griffith Sciences Industry Collaborative Grant aimed at developing collaborations with industry partners/end-users. Both ATP...

15:06
Couples can conceive even when all conventional fertility techniques have failed, according to a study just published in the Asian Journal of Andrology, detailing a breakthrough procedure called Sperm Mapping, which can help men diagnosed as...

13:00
Barrow Neurological Institute has initiated a $50 million effort, supported by the single largest research grant in the history of brain tumor research, to seek a cure for the deadliest form of brain cancer. Funding from The Ben and Catherine Ivy...

11:58
Millipede, Inc., un fabricant de dispositifs médicaux à l'avant-garde de l'enrichissement de la boîte à outils du cardiologue interventionnel pour les cardio­pathies structurelles, a efficacement traité deux patients à l'aide de son système de pose...

11:54
Eli Lilly and Company announced that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 27th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Sep. 12-16, 2018, in...

11:00
DURHAM, N.C., Sept. 10, 2018 /PRNewswire-PRWeb/ -- A new study published today in Stem Cells Translational Medicine details a novel stem cell treatment with the potential to restore sight after a serious chemical burn to the eye. About half a...

09:00
Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between Taltz® (ixekizumab) and Tremfya® (guselkumab) in adult patients with moderate-to-severe plaque psoriasis....

07:30
IDEXX Laboratories, Inc. , the global leader in rapid microbiological testing for water, today announced that the IDEXX Pseudalert® method has been published as the International Organization for Standardization (ISO) worldwide standard 16266-2 for...

07:00
Alkermes plc today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the FDA-approved PD-1...

06:03
Stanford University School of Medicine and Unanimous AI  presented a new study today showing that a small group of doctors, connected by intelligence algorithms that enable them to work together as a "hive mind," could achieve higher diagnostic...

05:08
Millipede, Inc., a medical device company leading the way in adding to the structural heart toolbox for the interventional cardiologist, has successfully treated two patients utilizing its latest-generation delivery system which incorporates a fully...


8 septembre 2018

00:00
CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class CAR-Claudin18.2 T cell trial for treatment of pancreatic and...


7 septembre 2018

15:53
BloodCenter of Wisconsin, part of Versiti, is among four academic and research centers which will receive approximately $20 million over the next five years from the National Heart, Lung and Blood Institute, part of the National Institutes of Health...

12:24
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today announced data showing ZTlidotm (lidocaine topical system) 1.8% (ZTlido) demonstrated a statistically significant improved adhesion profile compared...

1 2 3 4 5 6 7 8 9 10 11 12